The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric CancerYamanaka T.a · Matsumoto S.b · Teramukai S.c, d · Ishiwata R.d · Nagai Y.d · Fukushima M.b-d
aInstitute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Departments of bTranslational Clinical Oncology and cClinical Trial Design and Management, Graduate School of Medicine, Kyoto University, Kyoto, and dTranslational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: In cancer patients, the balance between neutrophil (N) and lymphocyte (L) cell counts fluctuates with advancing disease. The objective of our study was to determine the prognostic implications of the N/L ratio in the peripheral blood of gastric cancer patients. Methods: Study participants were identified from a prospective cohort of patients with advanced gastric cancer in Japan (n = 1,220). Results: The median baseline N/L was 2.58 (range, 0.63–12.7). Univariate analysis revealed that patients with an N/L ≧2.5 (n = 644) had a significantly poorer prognosis than those with an N/L <2.5 (n = 576; log rank test, p = 0.019 × 10–12). The median survival times for these two groups were 239 (95% confidence interval, CI, 217–251 days) and 363 days (95% CI, 334–406 days), respectively, while the 1-year survival rates were 30 (95% CI, 26–34%) and 50% (95% CI, 45–54%), respectively. A multivariate Cox model established a significant relationship between the N/L ratio and survival (adjusted hazard ratio = 1.52; 95% CI, 1.32–1.75; p = 0.077 × 10–8). Conclusions: These results suggest that the N/L ratio is an independent prognostic factor in advanced gastric cancer. Measurement of this ratio may serve as a clinically accessible and useful biomarker for patient survival.
© 2008 S. Karger AG, Basel
- Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860–867.
- Petrie HT, Klassen LW, Kay HD: Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 1985;134:230–234.
- el-Hag A, Clark RA: Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 1987;139:2406–2413.
- Satomi A, Murakami S, Ishida K, Mastuki M, Hashimoto T, Sonoda M: Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol 1995;34:69–73.
- Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181–184.
- Hirashima M, Higuchi S, Sakamoto K, Nishiyama T, Okada H: The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Cancer Res Clin Oncol 1998;124:329–334.
- Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191–197.
- Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028–1030.
- Lasek WA, Plodziszewska M, Gorecki D, Jakobisiak M: Relationship between natural killer (NK) activity and eosinophil, neutrophil and lymphocyte level in human blood. Folia Haematol (Leipzig) 1985;112:907–912.
- Tabuchi T, Soma T, Yonekawa M, Komai T, Hashimoto T, Adachi M: Reduction of VX2 transplanted tumor by granulocyte depletion using extracorporeal circulation on rabbit models. Anticancer Res 1992;12:795–798.
- Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A: Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 1987;47:173–177.
- Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545.
- Di Carlo E, Forni G, Musiani P: Neutrophils in the antitumoral immune response. Chem Immunol Allergy 2003;83:182–203.
- Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, Matsushima K, Herlyn M: Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003;103:335–343.
- Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, Mignatti P: Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001;189:197–206.
- Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, Presta M, Albini A, Cassatella MA: Generation of biologically active angiostatin kringle 1–3 by activated human neutrophils. J Immunol 2002;168:5798–5804.
- Kay HD, Smith DL: Regulation of human lymphocyte-mediated natural killer (NK) cell activity. I. Inhibition in vitro by peripheral blood granulocytes. J Immunol 1983;130:475–483.
- Shau HY, Kim A: Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 1988;141:4395–4402.
Ietomi K: A study on the role of granulocytes in carcinoma-bearing hosts – G/L ratio as a new host indicator. J Jpn Soc Cancer Ther 1990;25:662–671.
- Toge T, Yamaguchi Y: Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep 2000;7:1157–1161.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.